Atlas Principals’s Gilead Sciences GILD Stock Holding History

Atlas Principals’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,000	Closed	-$1.62M	–	44
2021 Q1	$1.62M	Buy	+25,000	New	+$1.61M	0.58%	35

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Atlas Principals's GILD Position: Q2 2021 in Review

Atlas Principals sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 25,000 shares — an estimated $1.62M sold.

Atlas Principals first reported a position in GILD in Q1 2021 and held it in 1 quarter. The position peaked at $1.62M in Q1 2021. 1,544 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

Atlas Principals reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
Atlas Principals sold 25,000 Gilead Sciences shares in Q2 2021, an estimated $1.62M.
Atlas Principals first reported a position in Gilead Sciences in Q1 2021 and held it in 1 quarter.
Atlas Principals's Gilead Sciences position peaked at $1.62M in Q1 2021.
1,544 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on Atlas Principals's 13F filing for Q2 2021, filed 16 Aug 2021.